Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy - Summary - MDSpire
Advertisement
Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy
To evaluate the role of contrast-enhanced ultrasonography (CEUS) in assessing newly detected pulmonary lesions during chemoimmunotherapy for non-small cell lung cancer (NSCLC), particularly in the context of diagnostic dilemmas.
Key Findings:
CEUS showed rapid hyperenhancement and persistent hyperenhancement in the venous phase, suggesting an inflammatory process.
The interpretation was supported by microbiologic evidence of respiratory infection.
Marked regression of the lesion was observed on follow-up CT after anti-infective treatment, conducted shortly after the initial CEUS assessment.
Interpretation:
CEUS can provide valuable real-time perfusion information that aids in distinguishing between inflammatory and malignant lesions in patients undergoing chemoimmunotherapy, especially when integrated with other clinical data.
Limitations:
The study is based on a single case report, limiting generalizability and introducing potential bias.
Lack of comprehensive biochemical analysis of pleural fluid from the initial evaluation.
Conclusion:
CEUS may serve as an adjunctive tool in the evaluation of newly detected peripheral pulmonary lesions during chemoimmunotherapy, particularly when integrated with other clinical data and imaging modalities.
Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)
